What is the current stock price of DexCom, Inc. (DXCM)?

As of the latest market data, DexCom, Inc. (DXCM) is trading at $64.02. The stock has seen a loss of -2.53% today.

Does DexCom, Inc. (DXCM) pay a dividend?

Based on current data, DexCom, Inc. does not have a confirmed active dividend policy.

What is the market cap of DexCom, Inc.?

The current market capitalization of DexCom, Inc. (DXCM) is approximately unavailable.

DXCM

DexCom, Inc.·Healthcare

64.02

2.527%(−1.66)

Market Closed

66.50

3.874%(+2.48)

After Hours

Last Updated: — ET

52W L: $54.1152W H: $89.98

DXCM NEWS

prnewswire.com

1d ago

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

defenseworld.net

3d ago

Exchange Traded Concepts LLC Sells 8,031 Shares of DexCom, Inc. $DXCM

Exchange Traded Concepts LLC lessened its position in shares of DexCom, Inc. (NASDAQ: DXCM) by 80.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,000 shares of the medical device company's stock after selling 8,031 shares during the period. Exchange Traded Concepts

defenseworld.net

4d ago

Financial Analysis: Pacific Biosciences of California (NASDAQ:PACB) versus DexCom (NASDAQ:DXCM)

Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) and DexCom (NASDAQ: DXCM - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability. Volatility and Risk Pacific Biosciences of California

defenseworld.net

Apr 3

Banque Pictet & Cie SA Raises Stock Holdings in DexCom, Inc. $DXCM

Banque Pictet and Cie SA boosted its holdings in shares of DexCom, Inc. (NASDAQ: DXCM) by 58.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 109,823 shares of the medical device company's stock after purchasing an additional 40,411 shares during the

businesswire.com

Apr 2

Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

defenseworld.net

Mar 30

DexCom, Inc. $DXCM Shares Sold by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. reduced its stake in DexCom, Inc. (NASDAQ: DXCM) by 12.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 272,836 shares of the medical device company's stock after selling 37,468 shares during the period. Beacon Investment

Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Sector

Healthcare

Industry

Medical - Devices

Employees

10,200

IPO Date

2005-04-14

Beta

1.56

Websitewww.dexcom.com↗